A report from bioLIVE — the new UBM biomanufacturing and bioprocessing event — has forecasted that outsourcing will play an increasing role in the bio supply chain and that continuous manufacturing, API and process analytical technology (PAT) expertise will be vital to future growth.
Report
The report, which includes a collection of findings from a panel of experts, identified that the establishment of a sustainable pipeline of qualified staff into the rapidly maturing biologics supply chain is a key issue for the sector. Data from the 2018 BioPlan Associates Annual Survey identified three key areas where small molecule expertise could see cross industry benefits — ‘process control’ (33%), ‘quality management’ (30%) and ‘training operators and technicians’ (29%).